The content on this site is intended for healthcare professionals only
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients
New therapies for transfusion dependent MDS patients
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL
Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia
Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocytic leukaemia
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Results from the MEDALIST trial for patients with anaemia in MDS
